{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:42:36Z","timestamp":1762144956489,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060138"],"award-info":[{"award-number":["82060138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejphar.2025.177739","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T18:34:22Z","timestamp":1747506862000},"page":"177739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage"],"prefix":"10.1016","volume":"1000","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manna","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qipeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.ejphar.2025.177739_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000521836","article-title":"Optimal value for serum Anti-PLA2R antibody in primary membranous nephropathy: a multicenter observational study","volume":"53","author":"Chen","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177739_bib2","first-page":"1","article-title":"Treatment of idiopathic membranous nephropathy for moderate or severe proteinuria: a systematic review and network meta-analysis","author":"Chen","year":"2022","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177739_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177739_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2264939","article-title":"The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy","volume":"45","author":"Chen","year":"2023","journal-title":"Ren. Fail."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177739_bib5","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20175976","article-title":"Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy","volume":"50","author":"Cui","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177739_bib6","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177739_bib8","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1053\/j.ajkd.2015.07.006","article-title":"AJKD atlas of renal pathology: membranous nephropathy","volume":"66","author":"Fogo","year":"2015","journal-title":"Am. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177739_bib9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"The natural history of the non-nephrotic membranous nephropathy patient","volume":"4","author":"Hladunewich","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4S","key":"10.1016\/j.ejphar.2025.177739_bib10","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177739_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3904\/kjim.2020.366","article-title":"The optimal anti-phospholipase A2 receptor cutoff for the diagnosis of idiopathic membranous nephropathy: a single-center retrospective study","volume":"37","author":"Li","year":"2022","journal-title":"Kor. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-024-03670-3","article-title":"A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLA2R-associated membranous nephropathy","volume":"25","author":"Mei","year":"2024","journal-title":"BMC Nephrol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177739_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.pathol.2016.02.001","article-title":"Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis","volume":"48","author":"Ong","year":"2016","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","article-title":"Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy","volume":"115","author":"Peng","year":"2016","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177739_bib17","first-page":"186","article-title":"Outcome of idiopathic membranous nephropathy: a retrospective study","volume":"20","author":"Rozenberg","year":"2018","journal-title":"Isr. Med. Assoc. J."},{"issue":"4","key":"10.1016\/j.ejphar.2025.177739_bib18","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2025.177739_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177739_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.614","article-title":"Membranous nephropathy: pathogenesis and treatments","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-023-03206-1","article-title":"Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177739_bib22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.12998\/wjcc.v11.i3.566","article-title":"Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose rituximab: a single-center experience","volume":"11","author":"Wang","year":"2023","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.ejphar.2025.177739_bib23","article-title":"Prediction of immunotherapy response in idiopathic membranous nephropathy using deep learning-pathological and clinical factors","volume":"15","author":"Wei","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177739_bib24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/13543784.16.7.1099","article-title":"Tacrolimus in the treatment of idiopathic nephrotic syndrome","volume":"16","author":"Westhoff","year":"2007","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"2","key":"10.1016\/j.ejphar.2025.177739_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11255-019-02348-2","article-title":"Association of diabetes with failure to achieve complete remission of idiopathic membranous nephropathy","volume":"52","author":"Xie","year":"2019","journal-title":"Int. Urol. Nephrol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-020-01878-7","article-title":"The impact of coexisting diabetes mellitus on clinical outcomes in patients with idiopathic membranous nephropathy: a retrospective observational study","volume":"21","author":"Xie","year":"2020","journal-title":"BMC Nephrol."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177739_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.amjms.2021.09.008","article-title":"Immunosuppressive treatments for idiopathic membranous nephropathy: a pilot study according to histopathological stages","volume":"363","author":"Yan","year":"2022","journal-title":"Am. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-018-1011-5","article-title":"Clinical implications of pathological features of primary membranous nephropathy","volume":"19","author":"Zhang","year":"2018","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib29","article-title":"Comparison of tacrolimus with or without prednisone therapy in primary membranous nephropathy: a retrospective clinical study","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177739_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/0886022X.2019.1637758","article-title":"Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy","volume":"41","author":"Zou","year":"2019","journal-title":"Ren. Fail."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925004935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925004935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:29:43Z","timestamp":1762144183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925004935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"alternative-id":["S0014299925004935"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177739","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of immunotherapy for idiopathic membranous nephropathy based on risk stratification and pathological stage","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177739"}}